Literature DB >> 19553610

Interobserver agreement for the detection of optical coherence tomography features of neovascular age-related macular degeneration.

Praveen J Patel1, Andrew C Browning, Fred K Chen, Lyndon Da Cruz, Adnan Tufail.   

Abstract

PURPOSE: To investigate the interobserver agreement for the detection of optical coherence tomography (OCT) features of disease activity in patients with neovascular age-related macular degeneration (nAMD).
METHODS: This was a cross-sectional agreement study in which grading of OCT line scans from patients with nAMD was conducted by two retinal specialists before the patients received treatment. Scans were graded for the presence of features of nAMD disease activity (intraretinal cysts [IRC], subretinal fluid [SRF], diffuse retinal edema [DRE], retinal pigment epithelial detachment [PED], and subretinal tissue [SRT]).
RESULTS: Although scans from 78 patients were available for analysis, five patients were excluded because of a mean signal strength of <7. Two hundred seventy-eight line scans were analyzed from 73 patients (40 with cross-hair scan sets and 33 with radial line scan sets). Agreement for per line scan analysis was 77% for IRC (kappa = 0.41), 81% for SRF (kappa = 0.62), 91% for macular fluid (kappa = 0.28), 79% for DRE (kappa = 0.10), 90% for PED (kappa = 0.78), and 79% for SRT (kappa = 0.53). Both observers disagreed regarding the presence of macular fluid in one patient (with a cross-hair scan).
CONCLUSIONS: Interpretation of OCT line scans from patients with nAMD is subject to interobserver variability. However, when all line scans acquired are examined for the presence of fluid (IRC or SRF), there is a high level of agreement for the detection of macular fluid on a per patient basis.

Entities:  

Mesh:

Year:  2009        PMID: 19553610     DOI: 10.1167/iovs.09-3505

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  OCT-based deep learning algorithm for the evaluation of treatment indication with anti-vascular endothelial growth factor medications.

Authors:  Philipp Prahs; Viola Radeck; Christian Mayer; Yordan Cvetkov; Nadezhda Cvetkova; Horst Helbig; David Märker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-10       Impact factor: 3.117

Review 2.  [Deep learning to support therapy decisions for intravitreal injections].

Authors:  P Prahs; D Märker; C Mayer; H Helbig
Journal:  Ophthalmologe       Date:  2018-09       Impact factor: 1.059

3.  SDOCT imaging to identify macular pathology in patients diagnosed with diabetic maculopathy by a digital photographic retinal screening programme.

Authors:  Sarah Mackenzie; Christian Schmermer; Amanda Charnley; Dawn Sim; Martin Dumskyj; Stephen Nussey; Catherine Egan
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240

4.  Interobserver agreement in detecting spectral-domain optical coherence tomography features of diabetic macular edema.

Authors:  Ling Zhi Heng; Maria Pefkianaki; Maria Pefianaki; Philip Hykin; Praveen J Patel
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

5.  Detecting signs of retinal leakage in exudative AMD using Cirrus OCT versus SL SCAN-1, a novel integrated FD-OCT into a common slit lamp.

Authors:  M Stehouwer; F D Verbraak; R O Schlingemann; T G van Leeuwen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-23       Impact factor: 3.117

6.  Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema.

Authors:  Meng-Ju Tsai; Yi-Ting Hsieh; Elizabeth P Shen; Yi-Jie Peng
Journal:  J Ophthalmol       Date:  2017-07-27       Impact factor: 1.909

7.  Intra- and Intergrader Agreement for Detection of OCT Angiographic Characteristics Associated With Type 3 Neovascularization.

Authors:  Lisette M Smid; Mirjam E J van Velthoven; King T Wong; José P Martinez-Ciriano; Koenraad A Vermeer
Journal:  Transl Vis Sci Technol       Date:  2021-01-08       Impact factor: 3.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.